- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797029
A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh
A Randomized, Double-Blind, Placebo-Controlled Trial on the Clinical Efficacy and Safety of a Single Dose of Trivalent Seasonal Live-Attenuated Influenza Vaccine(LAIV) Among Children Aged 24 Through 59 Months in Bangladesh
This is a single center, multi-site, double-blind, parallel group, placebo-controlled trial of the clinical efficacy of trivalent Serum Institute of India, Ltd. (SIIL)live-attenuated influenza vaccine (LAIV) vaccine among children aged 24 through 59 months in Bangladesh.
Background:
- Burden: Within Bangladesh, community- based influenza surveillance identified 84.5 cases/1000 children-years among children <5 years, while 10% of clinical pneumonia cases were influenza positive in this age group.
- Knowledge gap: There has never been a randomized clinical efficacy trial of the SIIL LAIV vaccine conducted among children in a low-income country.
- Relevance: Another LAIV vaccine (made by MedImmune) has been shown to have high efficacy against laboratory-confirmed influenza among children. The SIIL LAIV has the potential to be an inexpensive intervention to prevent pediatric influenza disease.
Primary Hypothesis: In children aged 24 through 59 months in Bangladesh, LAIV is efficacious in reducing rates of symptomatic, laboratory-confirmed influenza (vaccine-matched strains) among children vaccinated with LAIV as compared to children vaccinated with a placebo through the first influenza season following vaccination.
Primary Objective: To determine the efficacy of LAIV in reducing rates of symptomatic, laboratory-confirmed influenza virus infection (vaccine-matched strains) among children receiving LAIV as compared to children receiving a placebo through the first influenza season following vaccination (through December 2013).
Methods: A total of 1761 children will be enrolled and randomized in a 2:1 ratio of LAIV to placebo beginning in March 2013. After vaccination, all children will be evaluated for reactions with one home visit four days post vaccination. Subsequently, all children will be monitored weekly for safety outcomes and illness signs at weekly field worker home visits through December 2013. An extended surveillance period was added to this study and, for participants consenting to additional follow-up, surveillance will extend through a second season (through September 2014). Participants with illness signs will be referred to the study clinic for evaluation using standardized diagnostic criteria and treatment by a study physician. Children meeting protocol-defined clinical Specimen Collection Criteria will have a nasopharyngeal wash specimen collected. Clinical specimens will be tested by Real time polymerase chain reaction (rRT-PCR) for evidence of influenza virus infection.
Primary Outcome measures/variables: Vaccine efficacy will be assessed against symptomatic, laboratory-confirmed influenza for all circulating virus strains.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh
- icddr, b Kamalapur
-
Matlab, Bangladesh
- icddr,b Matlab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female child at least 24 months of age and no older than 59 months of age at the time of study vaccination.
- A child whose parent or guardian's primary residence, at the time of study vaccinations, is within the Kamalapur surveillance site catchment area or Matlab service area and who intends to be present in the area for the duration of the trial.
- A child whose parent or legal guardian is willing to provide written informed consent prior to the participant's study vaccination.
Exclusion Criteria:
- Has any serious, active, medical conditions, including: a chronic disease of any body system, chronic infections such as tuberculosis, genetic disorders, such as Down's syndrome or other cytogenetic disorder, known or suspected disease of the immune system.
- Is receiving immunosuppressive agents, including systemic corticosteroids, during the month prior to study vaccination.
- Has a history of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with life-threatening reactions to previous influenza vaccinations.
- Has ever received influenza vaccine (LAIV or inactivated).
- History of Guillain-Barre syndrome
- Is receiving aspirin therapy or aspirin-containing therapy currently or two weeks before.
- Lives in household with somebody currently participating in a respiratory vaccination or antiviral study.
- Has current or past participation (within 2 months of trial enrollment visit) in any clinical trial involving a drug or biologic with activity against respiratory disease.
- History of a previous severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis.
- Has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the child or make it unlikely that the child would complete the study
Temporary Inclusion Contraindications:
- Concurrent febrile illness (measured temperature 38 degrees C axillary).
- Active wheezing illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
|
Experimental: Vaccine
|
A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains).
Time Frame: Through 7 to 9 months post-vaccination
|
Through 7 to 9 months post-vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety Profile of LAIV: Solicited and Unsolicited Local and Systemic Reactions
Time Frame: Through one week post-vaccination
|
Through one week post-vaccination
|
Safety Profile of LAIV: Immediate Reactions
Time Frame: 30 minutes post-vaccination
|
30 minutes post-vaccination
|
Safety Profile of LAIV: Serious Adverse Events
Time Frame: Through 7 to 9 months post-vaccination
|
Through 7 to 9 months post-vaccination
|
Safety Profile of LAIV: Protocol Defined Wheezing Illness
Time Frame: Through 7 to 9 months post-vaccination
|
Through 7 to 9 months post-vaccination
|
Percentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains)
Time Frame: Through 7 to 9 months post-vaccination
|
Through 7 to 9 months post-vaccination
|
The Clinical Characteristics of Influenza, Including Influenza Co-infections With Other Bacterial and Viral Respiratory Pathogens
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
The Viral Etiologies of Acute Respiratory and Febrile Illness
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Safety Profile of LAIV: Serious Adverse Events
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Safety Profile of LAIV: Protocol Defined Wheezing Illness
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Percentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains)
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains).
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among Children
Time Frame: Through 7 to 9 months post-vaccination
|
Through 7 to 9 months post-vaccination
|
Percentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among Children
Time Frame: Through 16 to 19 months post-vaccination
|
Through 16 to 19 months post-vaccination
|
Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains) Among Children
Time Frame: From approx. 6 months to approximately 19 months post-vaccination
|
From approx. 6 months to approximately 19 months post-vaccination
|
Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (All Strains) Among Children
Time Frame: From approx. 6 months to approximately 19 months post-vaccination
|
From approx. 6 months to approximately 19 months post-vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Abdullah Brooks, MD, MPH, Johns Hopkins University
Publications and helpful links
General Publications
- Rotrosen E, Zaman K, Feser J, Ortiz JR, Goswami D, Sharmeen AT, Rahman M, Lewis KDC, Rahman MZ, Barin B, Brooks WA, Neuzil KM. Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial. Clin Infect Dis. 2017 Nov 13;65(11):1914-1920. doi: 10.1093/cid/cix674.
- Brooks WA, Zaman K, Lewis KD, Ortiz JR, Goswami D, Feser J, Sharmeen AT, Nahar K, Rahman M, Rahman MZ, Barin B, Yunus M, Fry AM, Bresee J, Azim T, Neuzil KM. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2016 Dec;4(12):e946-e954. doi: 10.1016/S2214-109X(16)30200-5. Epub 2016 Oct 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAIV-CE-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on SIIL Live Attenuated Influenza Vaccine
-
PATHCenters for Disease Control and Prevention; Institut de Recherche pour le Developpement and other collaboratorsCompleted
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina
-
PATH Vaccine SolutionsJohns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal...Completed
-
National Center for Occupational Health and Infection...US Department of Veterans AffairsTerminated
-
Changchun BCHT Biotechnology Co.National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaboratorsCompleted
-
Imperial College LondonPublic Health EnglandCompletedInfluenza VaccinesUnited Kingdom
-
Imperial College Healthcare NHS TrustCompletedInfluenza | Vaccine Virus SheddingUnited Kingdom
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Changchun BCHT Biotechnology Co.Not yet recruiting